Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Approval strengthens the company’s growing international anti-infective portfolio
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science
The Minister emphasised that scientific institutions must actively communicate their achievements and engage with stakeholders
Subscribe To Our Newsletter & Stay Updated